Literature DB >> 11449353

Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.

H Benlalam1, N Labarrière, B Linard, L Derré, E Diez, M C Pandolfino, M Bonneville, F Jotereau.   

Abstract

Fifty-nine tumor-infiltrating lymphocyte (TIL) cultures established from melanoma-invaded lymph nodes were screened for recognition of 28 melanoma-associated antigens (MAA) in association with31 HLA molecules. Twenty-three (39%) TIL lines reacted to at least one melanoma antigen. Melanosomal proteins were recognized by 19 TIL populations and the most prominent responses against these proteins were directed against Melan-A/MART-1 (mainly in association with HLA-A*0201) and gp100 (in association with diverse HLA contexts). Ten TIL populations reacted against 10 tumor-specific antigens, in association with 8 different HLA molecules. HLA-A*0201 and B*3501-restricted responses were the most frequent with, respectively, 17 and 7 responses directed against 5 distinct antigens. Unexpectedly, the recognition by TIL of different MAA was frequently restricted by a single HLA in individual tumors, and there was no evidence for the existence of dominant MAA epitopes between tumors,except for Melan-A/MART-1 antigen. This analysis also led to the detection of 21 new HLA-peptide complexes recognized by melanoma TIL. This study, which is to our knowledge the most comprehensive analysis of TIL specificity to tumor antigens, has several implications for the design of immunotherapeutic strategies based on immunization against selected tumor epitopes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11449353     DOI: 10.1002/1521-4141(200107)31:7<2007::aid-immu2007>3.0.co;2-s

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

Review 1.  Advances in the treatment of metastatic melanoma: adoptive T-cell therapy.

Authors:  Chantale Bernatchez; Laszlo G Radvanyi; Patrick Hwu
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

2.  HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.

Authors:  José A Campillo; Jorge A Martínez-Escribano; Manuel Muro; Rosa Moya-Quiles; Luis A Marín; Olga Montes-Ares; Natalia Guerra; Paloma Sánchez-Pedreño; José F Frías; José A Lozano; Ana M García-Alonso; M Rocío Alvarez-López
Journal:  Immunogenetics       Date:  2005-12-20       Impact factor: 2.846

Review 3.  Immune Checkpoint Inhibitors in Melanoma: A Review of Pharmacokinetics and Exposure-Response Relationships.

Authors:  Cyril Leven; Maël Padelli; Jean-Luc Carré; Eric Bellissant; Laurent Misery
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

4.  Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.

Authors:  Smita S Chandran; Biman C Paria; Abhishek K Srivastava; Luke D Rothermel; Daniel J Stephens; Mark E Dudley; Robert Somerville; John R Wunderlich; Richard M Sherry; James C Yang; Steven A Rosenberg; Udai S Kammula
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

5.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

Review 6.  The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.

Authors:  Katy K Tsai; Adil I Daud
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

7.  Alteration of the immunological synapse in lung cancer: a microenvironmental approach.

Authors:  S Derniame; J-M Vignaud; G C Faure; M C Béné
Journal:  Clin Exp Immunol       Date:  2008-08-29       Impact factor: 4.330

Review 8.  Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Authors:  Jeanne Galaine; Christophe Borg; Yann Godet; Olivier Adotévi
Journal:  Vaccines (Basel)       Date:  2015-06-30

9.  Prognostic value of B cells in cutaneous melanoma.

Authors:  Sara R Selitsky; Lisle E Mose; Christof C Smith; Shengjie Chai; Katherine A Hoadley; Dirk P Dittmer; Stergios J Moschos; Joel S Parker; Benjamin G Vincent
Journal:  Genome Med       Date:  2019-05-28       Impact factor: 11.117

10.  MELOE-1 is a new antigen overexpressed in melanomas and involved in adoptive T cell transfer efficiency.

Authors:  Yann Godet; Agnès Moreau-Aubry; Yannik Guilloux; Virginie Vignard; Amir Khammari; Brigitte Dreno; Francine Jotereau; Nathalie Labarriere
Journal:  J Exp Med       Date:  2008-10-20       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.